Lung Cancer Clinical Guidelines
From staging workup to biomarker-directed therapy — a complete clinical reference for NSCLC and SCLC
Clinical Guideline Sections
Select a section to access the full treatment algorithm, trial data, and decision trees.
Workup & General Principles
Lung cancer screening (USPSTF, PLCOm2012), Lung-RADS v2026, Fleischner nodule follow-up, mediastinal staging, NSCLC pathology, molecular testing (Tier 1/2 biomarkers), MPE management, ILD-related lung cancer
Early-Stage NSCLC
Stage I surgery vs SABR vs ablation, perioperative chemo-IO, adjuvant osimertinib/alectinib (ADAURA, ALINA)
Stage III NSCLC
Resectable vs unresectable, concurrent CRT, PACIFIC/durvalumab consolidation, LAURA/osimertinib in EGFR+, perioperative IO
Stage IV NSCLC — Biomarker-Directed
Driver-directed 1L/2L/3L therapy across EGFR, ALK, ROS1, RET, MET, BRAF, HER2, KRAS G12C, and no-driver PD-L1 guided treatment
Small Cell Lung Cancer (SCLC)
Limited-stage concurrent CRT + durvalumab (ADRIATIC), extensive-stage chemo-IO (IMpower133, CASPIAN), tarlatamab 2L
Lung Cancer Calculator Hub
Clinical calculators for lung cancer care — performance status, geriatric assessment, comorbidity scoring, and supportive care tools.
Clinical reference only. These guidelines are intended to support, not replace, clinical judgment. Treatment decisions should be individualised based on patient-specific factors, local protocols, and multidisciplinary team input. Always apply clinical judgment and consult local institutional guidelines where applicable.